Wrap Text
Availability of Integrated Reporting Suite, B-BBEE Verification Certificate and Further Notice of Annual General Meeting
ASPEN PHARMACARE HOLDINGS LIMITED AND ITS SUBSIDIARIES
(Incorporated in the Republic of South Africa)
Registration number: 1985/002935/06
Share code: APN
ISIN: ZAE000066692
LEI: 635400ZYSN1IRD5QWQ94
(collectively “Aspen” or “the Company”)
AVAILABILITY OF INTEGRATED REPORTING SUITE, B-BBEE VERIFICATION CERTIFICATE AND FURTHER NOTICE OF
ANNUAL GENERAL MEETING
1. POSTING OF AGM NOTICE AND AVAILABILITY OF INTEGRATED REPORTING SUITE
Shareholders are advised that the Company’s Integrated Reporting Suite for the year ended 30 June 2026 has been
finalised and that the notice of the annual general meeting (“AGM”) to be held at its Durban offices on 3 December
2026 is in the process of being posted to shareholders, along with a set of abbreviated annual financial statements
(“AFS”). The following documents are now available on the Company's website www.aspenpharma.com (at the
following link https://www.aspenpharma.com/investor-information/):
- Integrated Report for the 2026 financial year;
- Governance and Remuneration Report for the 2026 financial year (incorporating the reports of the Social and
Ethics Committee and the Audit and Risk Committee);
- Sustainability Report for the 2026 financial year;
- Notice of AGM and proxy in respect of the AGM to be held on 3 December 2026;
- Reports of the Aspen Audit & Risk and Social & Ethics committees for the 2026 financial year;
- Full AFS for the 2026 financial year (shareholders are referred to the No Change Statement and Notice of AGM as
released on 2 October 2026); and
- Various other reports supplementary to the Integrated Report
(collectively, the “Integrated Reporting Suite”).
2. NOTICE OF AGM
Further notice is hereby given that the 28th AGM of the shareholders of the Company will be held at Aspen Place, 9
Rydall Vale Park, Douglas Saunders Drive, La Lucia Ridge Office Park, Durban, Kwa-Zulu Natal, on
Thursday, 3 December 2026 at 10:00. Should you choose to attend the meeting in person, please contact the
Company Secretary at RKhan2@aspenpharma.com / 031 580 8600 by no later than 10:00 on
Tuesday, 1 December 2026 in order for seating arrangements to be confirmed.
The record date on which a person must be registered as a shareholder in the register of the Company for purposes
of being entitled to attend and participate in, and speak and vote at, the meeting is Friday, 27 November 2026.
Accordingly, the last day to trade in order to be registered in the register of members of the Company and therefore
be eligible to participate in and vote at the AGM is Tuesday, 24 November 2026. Shareholders are requested, but are
not obliged, to submit their completed forms of proxy to the Company's transfer secretaries (JSE Investor Services)
before 10:00 on Tuesday, 1 December 2026.
Shareholders who, for whatever reason, experience postal delays and, as a consequence, do not receive the notice
of the AGM in time to submit proxy forms to the Company's share transfer secretaries (JSE Investor Services) are
requested to access the notice of AGM and the Integrated Reporting Suite referred to above on the Company's
website www.aspenpharma.com. A printable version of the Integrated Reporting Suite in PDF format can also be
emailed to shareholders upon request to the Company Secretary – RKhan2@aspenpharma.com or +27 31 580 8600.
Electronic participation
Shareholders or their proxies or representatives may participate in (but not vote at) the meeting by way of telephone
/ video conference call, and if they wish to do so:
- Must contact the Company Secretary (by email at the address RKhan2@aspenpharma.com) by no later than 10:00
on Friday, 27 November 2026 in order to obtain the meeting link in order to participate in the meeting;
- Will be required to provide reasonably satisfactory identification; and
- Will be billed separately by their own service providers for the costs incurred in respect of their telephone / video
call to participate in the meeting.
3. BROAD-BASED BLACK ECONOMIC EMPOWERMENT CERTIFICATE
Shareholders are hereby advised that, in accordance with section 13G(2) of the Broad-Based Black Economic
Empowerment Act 53 of 2003, as amended, the Company has completed its B-BBEE verification process and
achieved a Level 4 B-BBEE contributor status. The Company’s B-BBEE certificate has been published and is available
on the Company’s website at www.aspenpharma.com.
Durban
23 October 2026
Sponsor
Investec Bank Limited
Date: 23/10/2026 02:30:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
Sharenet Sites 
